Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D
Status:
Completed
Trial end date:
2019-08-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the drug Bortezomib to see how well it works. The
investigators want to find out what effects, good or bad, it has on patients with a limited
smoking history or who have a specific mutation associated with their lung cancer.